Advanced search
Publication Cover
OncoImmunology Volume 13, 2024 - Issue 1
Submit an article Journal homepage
765
Views
0
CrossRef citations to date
0
Altmetric
Author’s View

Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer

Erin M. Dickeya Division of Surgical Oncology, DeWitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USAView further author information
,
Anna Bianchia Division of Surgical Oncology, DeWitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USAView further author information
,
Haleh Amiriana Division of Surgical Oncology, DeWitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USAView further author information
,
Peter J. Hoseinb Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA;c Sylvester Comprehensive Cancer Center, Miami, FL, USAView further author information
,
Denise Faustmand Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USAView further author information
,
Roberta Brambillae The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USAView further author information
&
Jashodeep Dattaa Division of Surgical Oncology, DeWitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA;c Sylvester Comprehensive Cancer Center, Miami, FL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2869-1571View further author information
ORCID Icon show all
Article: 2326694 | Received 20 Jan 2024, Accepted 29 Feb 2024, Published online: 12 Mar 2024

References

  • Datta J, Bianchi A, De Castro Silva I, Deshpande NU, Cao LL, Mehra S, Singh S, Rafie C, Sun X, Chen X. et al. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer. Oncogene. 2022;41(28):3640–3. doi:10.1038/s41388-022-02368-w.
  • Bianchi A, De Castro Silva I, Deshpande NU, Singh S, Mehra S, Garrido VT, Guo X, Nivelo LA, Kolonias DS, Saigh SJ. et al. Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer. Cancer Discov. 2023;13(6):1428–1453. doi:10.1158/2159-8290.Cd-22-1046.
  • Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K. et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83(5):793–802. doi:10.1016/0092-8674(95)90192-2.
  • Baxter AE, Kaufmann DE. Tumor-necrosis factor is a master of T cell exhaustion. Nat Immunol. 2016;17(5):476–478. doi:10.1038/ni.3436.
  • Case K, Tran L, Yang M, Zheng H, Kuhtreiber WM, Faustman DL. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models. J Leukoc Biol. 2020;107(6):981–991. doi:10.1002/JLB.5MA0420-375RRRRR.
  • Freedman MH, Cohen A, Grunberger T, Bunin N, Luddy RE, Saunders EF, Shahidi N, Lau A, Estrov Z. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia. Br J Haematol. 1992;80(1):40–48. doi:10.1111/j.1365-2141.1992.tb06398.x.
  • Baxevanis CN, Voutsas I, Tsitsilonis O, Tsiatas M, Gritzapis A, Papamichail M. Compromised anti-tumor responses in tumor necrosis factor-α knockout mice. Eur J Immunol. 2000;30(7):1957–1966. doi:10.1002/1521-4141(200007)30:7<1957:AID-IMMU1957>3.0.CO;2-7.
  • Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, Körner H, Scheerens H, Hessel EM, Cyster JG. et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity. 2001;15(4):533–543. doi:10.1016/s1074-7613(01)00215-1.
  • Padrón LJ, Maurer DM, O’Hara MH, O’Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP. et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28(6):1167–1177. doi:10.1038/s41591-022-01829-9.
  • Aung KL, Fischer SE, Denroche RE, Jang G-H, Dodd A, Creighton S, Southwood B, Liang S-B, Chadwick D, Zhang A. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24(6):1344–1354. doi:10.1158/1078-0432.Ccr-17-2994.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.